CHICAGO — In this video, Sham Mailankody, MBBS, discusses results from the long-term follow-up of CARTITUDE-1 patients receiving ciltacabtagene autoleucel, or cilta-cel, for the treatment of relapsed or refractory multiple myeloma.
“A third of the patients were progression free and alive 5 plus years after receiving cilta-cel, which is really an unprecedented result for relapsed/refractory multiple myeloma,” Mailankody, a myeloma specialist and cellular therapist at Memorial Sloan Kettering Cancer Center, said. “Half of the patients were alive at more than 5 years of